Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amgen, Inc.
Data: Aranesp dosed every 2 weeks is comparable to Epoetin alfa dosed weekly
June 22nd, 2005
Amgen, Inc., (AMGN) announced that final results of a phase III, randomized, head-to-head study demonstrated that 200 mcg of Aranesp (darbepoetin alfa) administered every 2 weeks is as effective as 40,000 U of Epoetin alfa dosed once a week in boosting hemoglobin levels and reducing the need for red blood cell transfusions in cancer patients with chemotherapy-induced anemia. The data were presented at the 41st annual meeting of the American Society of Clinical Oncology (ASCO) (Abstract #8125). "This is the largest, randomized, head-to-head comparison of darbepoetin alfa dosed every 2 weeks to Epoetin alfa dosed weekly, as they are most often used in...
Source: Physician Law Weekly (2005-06-22)
|
